Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Mogamulizumab |
| Trade Name | Poteligeo |
| Synonyms | KW-0761|Mogamulizumab-kpkc |
| Drug Descriptions |
Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody that binds to and inhibits C-C chemokine receptor 4 (CCR4) signaling, which leads to inhibition of Tregs and enhancement of host antitumor immunity (PMID: 25496334). Poteligeo (mogamulizumab-kpkc) is FDA approved for adult patients with relapsed or refractory mycosis fungoides or Sezary syndrome (FDA.gov). |
| DrugClasses | |
| CAS Registry Number | 1159266-37-1 |
| NCIT ID | C62510 |